Press Release
13 Jan, 2020
123
On January 13, 2020, InnoCare announced that the National Drug Administration of China (NMPA) Drug Evaluation Center (CDE) has prioritized the new drug application (NDA) for Orelabrutinib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL). InnoCare co-founder, chairman and CEO Dr. Cui Jisong said: " We are very encouraged by the inclusion of Orelabrutinib in the priority review category.. This fully demonstrates the country's determination to encourage innovation and accelerate the launch of new drugs, so that Chinese patients will have access to international first-in-class new drugs as soon as possible. We will accelerate the market launch of Orelabrutinib and expand its indications to meet the urgent clinical needs of patients world-wide. " Orelabrutinib's NDA for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) was accepted by the NMPA in November 2019. This NDA was submitted based on data from a clinical trial: A Phase I/II clinical study to investigate the safety, tolerability and pharmacokinetics/pharmacodynamics of ICP-022 in Chinese patients with relapsed/refractory chronic lymphoblastic leukemia (CLL)/small lymphoblastic lymphoma (SLL) (Registration No. CTR20180263). A number of global clinical studies on Orelabrutinib are ongoing. The purpose of drug priority review is to accelerate the development and marketing of clinically needed drugs with significant therapeutic advantages. The national drug administration department will prioritize the review and verification of these urgently needed drugs.
2180
20 Nov, 2019
117
On November 20, 2019, InnoCare announced that the NMPA has accepted the NDA of Orelabrutinib (ICP-022) for the treatment of patients with r/r CLL/SLL.
1182
05 Oct, 2019
65
InnoCare announced that it will present clinical data on its investigational BTK inhibitor Orelabrutinib (ICP-022) at the 61st ASH Annual Meeting, Dec. 7-10 in USA.
1183
01 Oct, 2019
26
InnoCare announced that Dr. Xiangyang Chen, who has over 20 years’ experience in biomedical research, was promoted to CTO.
1184
03 Jun, 2019
11
InnoCare, a leading innovator for global biopharmaceutical drugs, is proud to announce the appointment of Shaojing Tong as Chief Financial Officer (CFO). Mr. Tong has been a leading healthcare research analyst for the Asia-market and has extensive knowledge of the industry. Reporting directly to the CEO, Dr. Jasmine Cui, Mr. Tong will be responsible for the financial strategy development, risk management, and investment analysis. Mr. Tong is considered one of Hong Kong’s top research analysts for the entire biopharmaceutical and healthcare sector, repeatedly being ranked in the “Best Analyst Team” of the Asian healthcare industry. Mr. Tong has many years of experience in managing investment analyst teams and has acquired comprehensive knowledge of the industries history, value chains, and developmental trends. Before joining InnoCare, Mr. Tong served as an executive director and industry analyst at UBS China, where he covered medical companies for both the Hong Kong and A-class China markets. Prior to UBS, Mr. Tong was a healthcare research analyst for Bank of America Merrill Lunch (Hong Kong) and Michael Partners (New York). Preceding his financial career, Mr. Tong worked in drug development for CADUS Pharmaceuticals (New York). Mr. Tong received a Bachelor of Science degree in materials science and engineering from the University of Science and Technology of China. He obtained a Master’s degree in chemistry at the University of Pittsburg, and a Master of Business Administration (MBA) from New York University. “We are very pleased to have Mr. Tong onboard,” said Dr. Cui, CEO and Chairman of InnoCare, “His extensive knowledge and unique insight of the biopharmaceutical industry will help cement a strong financial foundation for InnoCare so that we can continuously build towards our goal of becoming a global leader for innovative drugs.” “I am honored to be a member of InnoCare and work with such an outstanding team,” Mr. Tong said, “InnoCare is a leader among Chinese innovative pharmaceutical companies, establishing a wealth of product pipeline in a very short amount of time. I look forward to joining such an experienced and passionate team, and will advance InnoCare’s goal of providing safe, effective, and affordable drugs for patients around the world.”
2119